Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Inhibrx Biosciences Inc ( (INBX) ) just unveiled an update.
On April 1, 2025, Inhibrx Biosciences, Inc. announced the appointment of David J. Matly as President, effective immediately, while he continues his role as Chief Commercial and Business Development Officer. This strategic move is expected to leverage Matly’s extensive experience in commercial launch and business development, enhancing the company’s market position. Concurrently, Brendan P. Eckelman resigned as Chief Scientific Officer on March 31, 2025, to establish a new private biotechnology company, marking a significant shift in the company’s leadership dynamics.
More about Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc. operates in the biotechnology industry, focusing on commercial, medical affairs, market access, and business development functions. The company is involved in the development and commercialization of biotechnological products and services.
YTD Price Performance: -8.26%
Average Trading Volume: 92,627
Technical Sentiment Signal: Strong Buy
Current Market Cap: $202.5M
See more data about INBX stock on TipRanks’ Stock Analysis page.